Published September 20, 2020 | Version v1
Journal article Open

Gut microbiota steroid sexual dimorphism and its impact on gonadal steroids: influences of obesity and menopausal status

  • 1. Department of Endocrinology, Diabetes and Nutrition, Departament de Ciències Mèdiques, Hospital of Girona "Dr JosepTrueta", Girona Biomedical Research Institute (IdibGi), University of Girona, Carretera de França s/n, 17007, Girona, Spain
  • 2. Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Cordoba, Spain
  • 3. Department of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain
  • 4. Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain

Description

Background: Gonadal steroid hormones have been suggested as the underlying mechanism responsible for the sexual dimorphism observed in metabolic diseases. Animal studies have also evidenced a causal role of the gut microbiome and metabolic health. However, the role of sexual dimorphism in the gut microbiota and the potential role of the microbiome in influencing sex steroid hormones and shaping sexually dimorphic susceptibility to disease have been largely overlooked. Although there is some evidence of sex-specific differences in the gut microbiota diversity, composition, and functionality, the results are inconsistent. Importantly, most of these studies have not taken into account the gonadal steroid status. Therefore, we investigated the gut microbiome composition and functionality in relation to sex, menopausal status, and circulating sex steroids.

Results: No significant differences were found in alpha diversity indices among pre- and post-menopausal women and men, but beta diversity differed among groups. The gut microbiota from post-menopausal women was more similar to men than to pre-menopausal women. Metagenome functional analyses revealed no significant differences between post-menopausal women and men. Gonadal steroids were specifically associated with these differences. Hence, the gut microbiota of pre-menopausal women was more enriched in genes from the steroid biosynthesis and degradation pathways, with the former having the strongest fold change among all associated pathways. Microbial steroid pathways also had significant associations with the plasma levels of testosterone and progesterone. In addition, a specific microbiome signature was able to predict the circulating testosterone levels at baseline and after 1-year follow-up. In addition, this microbiome signature could be transmitted from humans to antibiotic-induced microbiome-depleted male mice, being able to predict donor's testosterone levels 4 weeks later, implying that the microbiota profile of the recipient mouse was influenced by the donor's gender. Finally, obesity eliminated most of the differences observed among non-obese pre-menopausal women, post-menopausal women, and men in the gut microbiota composition (Bray-Curtis and weighted unifrac beta diversity), functionality, and the gonadal steroid status.

Conclusions: The present findings evidence clear differences in the gut microbial composition and functionality between men and women, which is eliminated by both menopausal and obesity status. We also reveal a tight link between the gut microbiota composition and the circulating levels of gonadal steroids, particularly testosterone.

Video Abstract

Files

40168_2020_913_MOESM6_ESM.jpg

Files (7.6 MB)

Name Size Download all
md5:34dd7a1d2c8064164c0bf164d1630693
16.0 kB Download
md5:8207405b62c94d8063130826637dd8c5
415.0 kB Download
md5:254783462af32e728f97b2294e0731af
406.0 kB Download
md5:152025b7ace7873a30abb8294e28f8dd
407.8 kB Download
md5:9441bbd4ef3315aff98c27eebb8b8426
15.8 kB Download
md5:0a52de3e1571888a727d58fbfb724e88
691.8 kB Preview Download
md5:9c45aa25d25b35615db7af183f491834
749.0 kB Preview Download
md5:2346cd0c82c8e49ceb2d25782baed953
669.7 kB Preview Download
md5:a0d8207be56aa0a71cead0c70db0858a
644.9 kB Preview Download
md5:1e472c8946745b4a917b8163f63df4b5
3.5 MB Preview Download
md5:e95ca138afc214b15840ca1af0e097dd
21.5 kB Download

Additional details

Funding

European Commission
NEUROPAIN - Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system 602891